A Phase 3b/4,Multi-center, Double-blind, Randomized, Parallel Group Study Of Tofacitinib (Cp-690,550) In Subjects With Ulcerative Colitis In Stable Remission
Phase of Trial: Phase III/IV
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms RIVETING STUDY
- Sponsors Pfizer
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.
- 07 Nov 2017 Planned End Date changed from 14 Dec 2019 to 1 Dec 2021.
- 15 Sep 2017 New trial record